Publications for 2025
Name of journal/ conference
Published date
Publication type
Title
Subspecialty
GenesisCare authors
DOI
Frontiers in Endocrinology
10.3389/fen- do.2025.1662247
Editorial: Functional neuroendocrine tumors
23/7/2025
Theranostics
Journal Article
Singh A
Evaluating Monaco 6.2.2 in complex radiotherapy across matched LINACs: improved MLC modelling and dose accuracy with virtual source model 2.0
10.1007/s13246- 025-01602-5
Radiation Oncology
Spinger Nature Link
21/7/2025
Journal Article
Munoz L,
Swallowing and Communication Outcomes Post Chemoradiotherapy for Low-Risk Human Papillomavirus (HPV)-Associated Oropharyngeal Squamous Cell Carcinoma: A Substudy of TROG 12.01 The PANEN nomogram: clinical decision support for patients with metastatic pancreatic neuroendocrine neoplasm referred for peptide receptor radionuclide therapy
PubMed - National Center for Biotechnology Information
Radiation Oncology
15/7/2025
Journal Article
June Corry, Lizbeth Kenny
10.1002/hed.28245
Frontiers in Endocrinology
10.3389/fen- do.2025.1514792
24/6/2025
Theranostics
Journal Article
Singh, A
Clinical and Experimental Dermatology
Radiation Oncology
10.1093/ced/ llaf261
Scalp hair repigmentation after radiotherapy
16/6/2025
Journal Article
I Porter
Translating advocacy into action: exploring oncology healthcare professionals’ awareness and use of the Clinical Oncology Society of Australia position statement on exercise in cancer care
Supportive Care in Cancer
10.1007/s00520- 025-09633-0
14/6/2025
Other
Journal Article
Zissiadis Y
Radiotherapy and time to initial treatment following a cancer diagnosis among First Nations Australians: results from a population based analysis
Radiation Oncology
10.1186/s13690- 025-01638-9
Archives of Public Health
6/6/2025
Journal Article
Baxi S
International Journal of Radiation Oncology Biology Physics
Adapting an Adaptive Department: Making It Work in an “Everyday” Department
Radiation Oncology
10.1016/j.ijro- bp.2025.02.018
6/6/2025
Journal Article
de Leon J, Twentyman T
The New England Journal of Medicine
Adjuvant Cemiplimab or Placebo in High- Risk Cutaneous Squamous-Cell Carcinoma
Medical Oncology
10.1056/NE- JMoa2502449
31/5/2025
Journal Article
Gerard Adams
American Society of Clinical Oncology - ASCO 2025
Phase 3 trial of adjuvant cemiplimab versus placebo for high-risk cutaneous squamous cell carcinoma (C-POST)
Medical Oncology
Abstract: Oral Presentation
30/5/2025
Gerard Adams
46
47
Made with FlippingBook Annual report maker